RESUMO
Neutralizing antibodies (nAbs) are a critical part of coronavirus disease 2019 (COVID-19) research as they are used to gain insight into the immune response to severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infections. Among the technologies available for generating nAbs, DNA-based immunization methods are an alternative to conventional protocols. In this pilot study, we investigated whether DNA-based immunization by needle injection in rabbits was a viable approach to produce a functional antibody response. We demonstrated that three doses of DNA plasmid carrying the gene encoding the full-length spike protein (S) or the receptor binding domain (RBD) of SARS-CoV-2 induced a time-dependent increase in IgG antibody avidity maturation. Moreover, the IgG antibodies displayed high cross neutralization by live SARS-CoV-2 and pseudoviruses neutralization assays. Thus, we established a simple, low cost and feasible DNA-based immunization protocol in rabbits that elicited high IgG avidity maturation and nAbs production against SARS-CoV-2, highlighting the importance of DNA-based platforms for developing new immunization strategies against SARS-CoV-2 and future emerging epidemics.
Assuntos
COVID-19 , SARS-CoV-2 , Animais , Coelhos , SARS-CoV-2/genética , Anticorpos Neutralizantes , Projetos Piloto , COVID-19/prevenção & controle , Imunoglobulina G , ImunizaçãoRESUMO
As seqüelas neurológicas da cinomose canina são consideradas irreversíveis e têm sido tratadas sintomaticamente, quando não há indicação de eutanásia, o que ocorre na maioria dos casos de seqüelas graves. Visando desenvolver uma nova abordagem terapêutica, testamos a injeção de células mononucleares de medula óssea alogeneicas extraídas de 5 cães doadores saudáveis, em 11 cães com seqüelas neurológicas com pré-diagnóstico de cinomose, sendo 7 com manifestações clínicas recentes e 4 com sinais clínicos crônicos. Dos 7 animais com seqüelas agudas ou recentes, 5 apresentaram remissão completa dos sinais clínicos e 2 melhora parcial e momentânea. Dos animais com sinais crônicos, 3 apresentaram melhora visível na primeira semana após o transplante, contudo, 2 deles, após curto período de estabilidade, apresentaram novamente os mesmos sinais clínicos vistos antes do transplante. Este protocolo mostrou-se bastante promissor para o tratamento de seqüelas neurológicas de cinomose canina(AU)
The neurologic sequels of canine distemper are currently considered irreversible, and are usually treated with palliative therapies when euthanasia is not recommended, what happens in the majority of severe cases. Aiming to develop a new therapeutic approach, we tested the systemic injection of allogeneic bone marrow mononuclear cells extracted from 5 healthy dogs, in 11 dogs with severe neurologic sequels with distemper previous diagnosis. 7 dogs had recent clinical manifestations and 4 had chronic signs. In the group of 7 animals with acute or recent sequels, 5 had complete remission of clinical signs and 2 had partial recovery. In the group with chronic sequels, 3 had visible recovery in the first week after transplantation, but 2 of them, after a short period of stability, presented again the same clinical signs seen before the transplantation. This protocol has demonstrated to be very promising for the treatment of neurologic sequels of canine distemper(AU)
Assuntos
Animais , Cães , Cinomose , Cães , Células da Medula Óssea , Transplante de Medula Óssea/veterináriaRESUMO
As seqüelas neurológicas da cinomose canina são consideradas irreversíveis e têm sido tratadas sintomaticamente, quando não há indicação de eutanásia, o que ocorre na maioria dos casos de seqüelas graves. Visando desenvolver uma nova abordagem terapêutica, testamos a injeção de células mononucleares de medula óssea alogeneicas extraídas de 5 cães doadores saudáveis, em 11 cães com seqüelas neurológicas com pré-diagnóstico de cinomose, sendo 7 com manifestações clínicas recentes e 4 com sinais clínicos crônicos. Dos 7 animais com seqüelas agudas ou recentes, 5 apresentaram remissão completa dos sinais clínicos e 2 melhora parcial e momentânea. Dos animais com sinais crônicos, 3 apresentaram melhora visível na primeira semana após o transplante, contudo, 2 deles, após curto período de estabilidade, apresentaram novamente os mesmos sinais clínicos vistos antes do transplante. Este protocolo mostrou-se bastante promissor para o tratamento de seqüelas neurológicas de cinomose canina
The neurologic sequels of canine distemper are currently considered irreversible, and are usually treated with palliative therapies when euthanasia is not recommended, what happens in the majority of severe cases. Aiming to develop a new therapeutic approach, we tested the systemic injection of allogeneic bone marrow mononuclear cells extracted from 5 healthy dogs, in 11 dogs with severe neurologic sequels with distemper previous diagnosis. 7 dogs had recent clinical manifestations and 4 had chronic signs. In the group of 7 animals with acute or recent sequels, 5 had complete remission of clinical signs and 2 had partial recovery. In the group with chronic sequels, 3 had visible recovery in the first week after transplantation, but 2 of them, after a short period of stability, presented again the same clinical signs seen before the transplantation. This protocol has demonstrated to be very promising for the treatment of neurologic sequels of canine distemper